AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for m7GpppN-mRNA hydrolase

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

We employ our advanced, specialised process to create targeted libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.

Our library stands out due to several important features:

  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

Q8IU60

UPID:

DCP2_HUMAN

Alternative names:

Nucleoside diphosphate-linked moiety X motif 20; mRNA-decapping enzyme 2

Alternative UPACC:

Q8IU60; C9J778; Q6P2D4; Q7Z5W5; Q8NBG5

Background:

The m7GpppN-mRNA hydrolase, also known as mRNA-decapping enzyme 2, is a pivotal decapping metalloenzyme. It catalyzes the removal of the 7-methyl guanine cap from mRNAs, a critical step for mRNA degradation and turnover. This enzyme's activity is essential for normal mRNA decay and nonsense-mediated mRNA decay, highlighting its role in gene expression regulation.

Therapeutic significance:

Understanding the role of m7GpppN-mRNA hydrolase could open doors to potential therapeutic strategies. Its crucial function in mRNA turnover and stability positions it as a key target for modulating gene expression, offering avenues for intervention in diseases where gene expression is dysregulated.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.